A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris
NCT ID: NCT02758041
Last Updated: 2017-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
85 participants
INTERVENTIONAL
2016-02-29
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02219074
Sebacia Postmarket Study of Real-World Use
NCT03818555
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02217228
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
NCT03303170
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sebacia Microparticles
Sebacia Microparticles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sebacia Microparticles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Moderate to moderately-severe facial inflammatory acne vulgaris
3. Fitzpatrick skin phototype I-III
Exclusion Criteria
2. Tattoo in the treatment area
3. Active skin disease, excessive scarring or excess facial hair in the treatment area
4. Certain current or recent acne treatments
5. Recent light treatments including Intense Pulsed Light or other lasers, microdermabrasion or chemical peels in the treatment area
6. Contraindicated for laser treatment, or is unable or unwilling to avoid excessive sun exposure or tanning bed use
7. Known allergy to gold
16 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sebacia, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merete Haedersdal, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, Bispebjerg Hospital, Univ of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lasercenter North
Aalborg, , Denmark
Department of Dermatology, Bispebjerg Hospital, Univ of Copenhagen
Copenhagen, , Denmark
SKINPULSE Dermatology Laser & Beauty Center
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEB-0294CH, SEB-0400
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.